GO:0060339 negative regulation of type I interferon-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060339 describes any process that decreases the rate, frequency or extent of type I interferon-mediated signaling, a central antiviral and immunoregulatory cascade [1,4].
• Negative regulation of type I IFN signaling is essential to prevent excessive inflammation and autoimmunity while allowing effective antiviral defense [1,5].
• Multiple mechanisms exist, including ubiquitin-mediated degradation of TBK1 by NLRP4-DTX4, inhibition of IRAK1 by SHP-1, and viral proteins such as rotavirus NSP1 that block STAT1 activation.
• Host long noncoding RNAs, such as NR_033736, can modulate type I IFN-mediated gene transcription and influence anti-Cryptosporidium defense.
• The aryl hydrocarbon receptor (AhR) constitutively constrains type I IFN-mediated antiviral innate defense, linking environmental sensing to IFN regulation.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect these regulatory mechanisms and identify therapeutic targets [4,5].
Description
Type I interferons (IFN-I), including IFN-α and IFN-β, are pleiotropic cytokines that orchestrate antiviral and immunomodulatory responses. The signaling pathway they trigger must be tightly controlled to avoid immunopathology. GO:0060339, negative regulation of type I interferon-mediated signaling pathway, encompasses all processes that decrease the rate, frequency or extent of this pathway [1,4]. Dysregulation of this negative regulation is associated with viral susceptibility, chronic inflammation, and autoimmunity [1,5]. Understanding the molecular players that restrain IFN-I signaling is therefore critical for both basic immunology and therapeutic development [4,8].
negative regulation of type I interferon-mediated signaling pathway At A Glance
| GO ID | GO:0060339 |
|---|---|
| GO term | negative regulation of type I interferon-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | negative regulation of type I interferon-mediated signalling pathway |
| Major function | Dampening or terminating type I IFN signaling to prevent excessive inflammation and autoimmunity while preserving antiviral defense |
| Key negative regulators | NLRP4, DTX4, SHP-1 (PTPN6), DCST1, AhR, lncRNA NR_033736, rotavirus NSP1 |
| Pathway context | Acts on the type I IFN signaling cascade, including TBK1, IRAK1, STAT1, and ISG transcription |
| Disease relevance | Viral infections, autoimmunity, chronic inflammation, and cancer immunosurveillance |
What Is GO:0060339?
According to the Gene Ontology, GO:0060339 (negative regulation of type I interferon-mediated signaling pathway) is any biological process that decreases the rate, frequency or extent of a type I interferon-mediated signaling pathway. This includes mechanisms that act at any step of the cascade, from interferon binding to receptor, through JAK-STAT activation, to transcriptional induction of interferon-stimulated genes (ISGs) [1,4,5].
Why Is negative regulation of type I interferon-mediated signaling pathway Important in Cell Biology?
Negative regulation of type I interferon signaling is crucial for maintaining immune homeostasis. Without proper brakes, IFN-I responses can cause tissue damage, autoimmunity, and chronic inflammation [1,5]. Conversely, excessive negative regulation can impair antiviral defense and promote viral persistence. Thus, understanding GO:0060339 provides insights into host-pathogen interactions and identifies targets for therapeutic intervention in infectious and autoimmune diseases [4,8].
• Prevents IFN-I-driven autoimmunity and inflammatory diseases [1,5].
• Shapes the outcome of viral infections by balancing antiviral defense and immunopathology.
• Involved in host defense against parasites such as Cryptosporidium via lncRNA regulation.
• Provides targets for antiviral therapies and vaccine adjuvants.
• Links environmental factors (e.g., AhR ligands) to immune regulation.
• Modulates cancer immunosurveillance and response to immunotherapy.
• Key for understanding mechanisms of viral immune evasion.
• Offers opportunities for CRISPR-based functional genomics [4,5].
What Happens During negative regulation of type I interferon-mediated signaling pathway?
Initiation of type I IFN signaling
In simple terms: Type I interferons bind to their receptor and start a chain of signals inside the cell.
Type I interferons (IFN-α/β) bind to the IFNAR receptor, activating JAK kinases and leading to phosphorylation of STAT1 and STAT2. These form a complex with IRF9 (ISGF3) that translocates to the nucleus and induces interferon-stimulated genes (ISGs) [1,4].
Negative regulation at the kinase level
In simple terms: Some proteins put brakes on the signaling by destroying key kinases.
NLRP4 targets the kinase TBK1 for ubiquitination and degradation via the E3 ligase DTX4, thereby dampening IFN-I production. Similarly, SHP-1 (PTPN6) inhibits IRAK1 to promote TLR- and RIG-I-activated production of type I interferon, acting as a negative regulator.
Negative regulation by host noncoding RNAs
In simple terms: Long noncoding RNAs can act as sponges or scaffolds to reduce interferon responses.
The host long noncoding RNA NR_033736 regulates type I interferon-mediated gene transcription and modulates intestinal epithelial anti-Cryptosporidium defense, illustrating a layer of negative regulation by noncoding RNAs.
Viral interference with IFN signaling
In simple terms: Viruses make proteins that block interferon signaling to escape immunity.
Rotavirus NSP1 protein inhibits interferon-mediated STAT1 activation, preventing ISG expression and facilitating viral replication. This represents a pathogen-encoded negative regulation of the pathway.
Environmental and metabolic modulation
In simple terms: Environmental sensors like AhR can suppress interferon responses.
Constitutive aryl hydrocarbon receptor (AhR) signaling constrains type I interferon-mediated antiviral innate defense, linking environmental cues to negative regulation of IFN-I.
Key Genes Involved in GO:0060339 negative regulation of type I interferon-mediated signaling pathway
The following genes and proteins are experimentally validated negative regulators of type I interferon-mediated signaling, based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NLRP4 | Targets TBK1 for DTX4-mediated ubiquitination and degradation | Negative regulator of IFN-I production; potential target in autoimmunity |
| DTX4 | E3 ubiquitin ligase that partners with NLRP4 to degrade TBK1 | Modulates IFN-I signaling; druggable ubiquitin pathway |
| PTPN6 (SHP-1) | Phosphatase that inhibits IRAK1 to promote IFN-I production | Negative regulator of TLR/RIG-I signaling; role in inflammation |
| DCST1 | E3 ubiquitin ligase identified as a negative regulator of type I IFN signaling | Novel target for IFN-related diseases |
| AHR | Aryl hydrocarbon receptor; constitutive signaling constrains IFN-I antiviral defense | Links environmental ligands to immune suppression |
| NR_033736 | Long noncoding RNA that regulates IFN-I-mediated gene transcription | Modulates anti-Cryptosporidium defense in intestinal epithelium |
| NSP1 (rotavirus) | Viral protein that inhibits STAT1 activation | Viral immune evasion mechanism |
| STAT1 | Transcription factor activated by IFN-I; target of negative regulation | Central node in IFN signaling; mutations cause immunodeficiency |
| TBK1 | Kinase essential for IFN-I production; degraded by NLRP4-DTX4 | Key target for negative regulation |
| IRAK1 | Kinase in TLR/RIG-I pathways; inhibited by SHP-1 | Regulates IFN-I production |
| IFNAR1 | Type I IFN receptor subunit; upstream of signaling | Target for negative regulation at receptor level |
| IFNAR2 | Type I IFN receptor subunit; upstream of signaling | Target for negative regulation at receptor level |
| JAK1 | Janus kinase activated by IFNAR; can be negatively regulated | Potential target for modulation |
| TYK2 | Janus kinase activated by IFNAR; can be negatively regulated | Potential target for modulation |
| IRF9 | Part of ISGF3 complex; downstream of IFN-I signaling | Transcription factor for ISGs |
| IL1B | Interleukin-1 beta; amplifies IFN-alpha-induced antiviral responses | Cytokine that modulates IFN signaling |
| SOCS1 | Suppressor of cytokine signaling; classical negative regulator of JAK-STAT | Well-known negative feedback regulator |
| USP18 | Ubiquitin-specific protease; negative regulator of IFN-I signaling | Key brake on IFN responses |
How Is negative regulation of type I interferon-mediated signaling pathway Regulated?
The negative regulation of type I interferon signaling is itself tightly controlled. For example, IL-1β can amplify IFN-α-induced antiviral responses, indicating cross-talk between inflammatory cytokines and IFN regulation. Additionally, host defense against viral infection involves interferon-mediated down-regulation of sterol biosynthesis, which may indirectly affect IFN signaling. These layers of regulation ensure a balanced immune response.
negative regulation of type I interferon-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NLRP4 | Autoimmunity, excessive IFN production | Knockout mice or cell lines to assess IFN levels |
| DTX4 | Autoinflammation, viral susceptibility | Knockout and point mutation models |
| PTPN6 (SHP-1) | Inflammatory diseases, TLR/RIG-I dysregulation | Knockout macrophages and dendritic cells |
| DCST1 | Cancer immunosurveillance, viral infection | Overexpression and knockout in tumor cells |
| AHR | Environmental immune suppression, viral susceptibility | Knockout and ligand-treated models |
Viral infections and immune evasion
Many viruses encode proteins that negatively regulate type I IFN signaling to evade host immunity. Rotavirus NSP1 inhibits STAT1 activation, blocking ISG expression and promoting viral replication. Understanding these mechanisms can inform antiviral strategies.
Autoimmunity and chronic inflammation
Defects in negative regulation of IFN-I signaling can lead to excessive IFN production and autoimmunity, such as systemic lupus erythematosus. NLRP4 and DTX4-mediated degradation of TBK1 is a key brake; its dysregulation may contribute to autoimmune pathology. SHP-1 also plays a role in preventing uncontrolled inflammation.
Parasitic infections
The long noncoding RNA NR_033736 regulates type I IFN-mediated gene transcription and modulates intestinal epithelial anti-Cryptosporidium defense, highlighting the importance of negative regulation in parasitic infections.
Cancer immunosurveillance
Type I IFN signaling is critical for cancer immunosurveillance. Negative regulators such as DCST1 may influence tumor immune evasion, and targeting these pathways could enhance immunotherapy.
From negative regulation of type I interferon-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate IFN-I signaling? | CRISPR knockout in HEK293T or THP-1 cells followed by IFN stimulation |
| What is the role of a specific phosphorylation site in negative regulation? | Point mutation knock-in via CRISPR |
| How does a negative regulator interact with TBK1? | Tagged knock-in (e.g., HA-tag) for co-IP |
| Can overexpression of a negative regulator suppress IFN responses? | CRISPRa or lentiviral overexpression |
| What is the impact of a viral protein on STAT1 activation? | Knockout of viral gene or host STAT1 |
| Does a lncRNA modulate IFN signaling? | CRISPR knockout of lncRNA locus |
How to Study the negative regulation of type I interferon-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify ISGs de-repressed upon knockout of negative regulator |
| Ubiquitinome profiling | Ubiquitination of proteins | Discover E3 ligases targeting IFN signaling components |
| Co-immunoprecipitation | Protein-protein interactions | Validate NLRP4-DTX4-TBK1 complex |
| Luciferase reporter assay | IFN-induced transcriptional activity | Screen for negative regulators |
| CRISPR knockout screen | Loss-of-function phenotypes | Identify novel negative regulators |
| Phospho-STAT1 immunoblot | STAT1 activation status | Assess viral inhibition of IFN signaling |
| qRT-PCR | mRNA levels of ISGs | Validate lncRNA-mediated regulation |
| Flow cytometry | Cell surface markers and viability | Measure IFN-induced apoptosis or protection |
Transcriptomic profiling (RNA-seq)
RNA sequencing after IFN stimulation in knockout versus wild-type cells can identify ISGs whose expression is de-repressed, revealing negative regulators [4,7].
Proteomics and ubiquitinome analysis
Global ubiquitome profiling has identified E3 ligases such as DCST1 as negative regulators of type I IFN signaling. Mass spectrometry can map ubiquitination sites on TBK1 and other targets.
Imaging and reporter assays
IFN-responsive luciferase reporters and fluorescence microscopy can visualize signaling activity and localization of negative regulators [1,5].
CRISPR screens
Genome-wide CRISPR knockout or activation screens coupled with IFN-induced cell death or reporter expression can uncover novel negative regulators.
How CRISPR Can Be Used to Study GO:0060339 negative regulation of type I interferon-mediated signaling pathway
Knockout
CRISPR knockout of candidate negative regulators (e.g., NLRP4, DTX4, PTPN6) in cell lines or primary cells can confirm their role in dampening IFN-I signaling. For example, knockout of DTX4 stabilizes TBK1 and enhances IFN production.
Point Mutation
Introducing point mutations in key residues (e.g., phosphorylation sites on TBK1 or STAT1) via CRISPR can dissect their contribution to negative regulation. This is useful for studying viral proteins like rotavirus NSP1.
Knock-in
Tagged knock-in (e.g., HA, FLAG, or GFP) of negative regulators allows endogenous-level expression and interaction studies. This can reveal dynamic regulation of proteins like SHP-1.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of negative regulators can suppress IFN responses, modeling states of immune suppression. This is valuable for studying AhR-mediated constraint.
How EDITGENE Supports negative regulation of type I interferon-mediated signaling pathway Research
Researchers studying negative regulation of type I interferon-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in dampening IFN responses. EDITGENE provides comprehensive CRISPR services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of type I interferon-mediated signaling pathway research.
Frequently Asked Questions About negative regulation of type I interferon-mediated signaling pathway
What is GO:0060339?
GO:0060339 is the Gene Ontology term for negative regulation of type I interferon-mediated signaling pathway, describing any process that decreases the rate, frequency or extent of type I IFN signaling [1,4].
What genes are involved in negative regulation of type I interferon signaling?
Key genes include NLRP4, DTX4, PTPN6 (SHP-1), DCST1, AHR, and the lncRNA NR_033736, among others [1,4,5,7,8].
How does NLRP4 negatively regulate type I interferon signaling?
NLRP4 targets the kinase TBK1 for ubiquitination and degradation via the E3 ligase DTX4, thereby reducing IFN-I production.
What is the role of SHP-1 in type I interferon signaling?
SHP-1 (PTPN6) inhibits IRAK1 to promote TLR- and RIG-I-activated production of type I interferon, acting as a negative regulator.
Can viruses inhibit type I interferon signaling?
Yes, rotavirus NSP1 protein inhibits interferon-mediated STAT1 activation, blocking ISG expression and facilitating viral replication.
What is the link between AhR and type I interferon?
Constitutive aryl hydrocarbon receptor (AhR) signaling constrains type I interferon-mediated antiviral innate defense, linking environmental cues to immune suppression.
How do long noncoding RNAs regulate type I interferon signaling?
The host lncRNA NR_033736 regulates type I interferon-mediated gene transcription and modulates intestinal epithelial anti-Cryptosporidium defense.
What diseases are associated with dysregulated negative regulation of type I IFN signaling?
Dysregulation is linked to autoimmunity, chronic inflammation, viral susceptibility, and cancer immunosurveillance [1,4,5,6].
What research methods are used to study negative regulation of type I IFN signaling?
Methods include RNA-seq, ubiquitinome profiling, co-immunoprecipitation, luciferase reporter assays, and CRISPR screens [4,5,7].
How can CRISPR help study negative regulation of type I IFN signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional validation of candidate negative regulators and their mechanisms [4,5,6,8].
Conclusion
GO:0060339, negative regulation of type I interferon-mediated signaling pathway, is a critical biological process that balances antiviral immunity and immune homeostasis. The diverse mechanisms, from ubiquitin-mediated degradation of TBK1 to viral interference with STAT1, highlight the complexity of this regulation. Understanding these pathways offers therapeutic opportunities for infectious diseases, autoimmunity, and cancer. EDITGENE provides advanced CRISPR tools to dissect these mechanisms and accelerate discovery.
References
- 1. Yamada T et al.. 2016. Constitutive aryl hydrocarbon receptor signaling constrains type I interferon-mediated antiviral innate defense.. Nat Immunol 17(6):687-94 PMID: 27089381
- 2. Robichon K et al.. 2020. Identification of Interleukin1β as an Amplifier of Interferon alpha-induced Antiviral Responses.. PLoS Pathog 16(10):e1008461 PMID: 33002089
- 3. Blanc M et al.. 2011. Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis.. PLoS Biol 9(3):e1000598 PMID: 21408089
- 4. Nair S et al.. 2016. Global functional profiling of human ubiquitome identifies E3 ubiquitin ligase DCST1 as a novel negative regulator of Type-I interferon signaling.. Sci Rep 6:36179 PMID: 27782195
- 5. Cui J et al.. 2012. NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4.. Nat Immunol 13(4):387-95 PMID: 22388039
- 6. Sen A et al.. 2014. Rotavirus NSP1 protein inhibits interferon-mediated STAT1 activation.. J Virol 88(1):41-53 PMID: 24131713
- 7. Li J et al.. 2021. A host cell long noncoding RNA NR_033736 regulates type I interferon-mediated gene transcription and modulates intestinal epithelial anti-Cryptosporidium defense.. PLoS Pathog 17(1):e1009241 PMID: 33481946
- 8. An H et al.. 2008. Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1.. Nat Immunol 9(5):542-50 PMID: 18391954
